BamSEC and AlphaSense Join Forces
Learn More

ANI Pharmaceuticals Inc.

NASDAQ: ANIP    
Share price (12/4/25): $82.74    
Market cap (12/4/25): $1.858 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.8
from 10-Q 4 pages Amendment No. 1 to Executive Employment Agreement
12/34/56
EX-10.7
from 10-Q 3 pages Amendment No. 1 to Executive Employment Agreement
12/34/56
EX-10.6
from 10-Q 3 pages Amendment No. 1 to Executive Employment Agreement
12/34/56
EX-10.5
from 10-Q 3 pages Amendment No. 1 to Executive Employment Agreement
12/34/56
EX-10.4
from 10-Q 4 pages Amendment No. 1 to Executive Employment Agreement
12/34/56
EX-10.3
from 10-Q 3 pages Amendment No. 1 to Executive Employment Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Amendment No. 1 to Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Amendment No. 1 to Executive Employment Agreement
12/34/56
EX-10.1
from S-8 9 pages Amended and Restated ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan
12/34/56
EX-10.1
from S-8 14 pages ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan
12/34/56
EX-10.5
from 10-Q 10 pages ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan Notice of Restricted Stock Grant
12/34/56
EX-10.4
from 10-Q 3 pages ANI Pharmaceuticals, Inc. (The “Company”) the Company’s Amended and Restated 2022 Stock Incentive Plan (The “Plan”) Sub-Plan for U.K. Employees
12/34/56
EX-10.1
from 8-K 20 pages Contingent Value Rights Agreement
12/34/56
EX-10.1
from 8-K 37 pages [Dealer]1
12/34/56
EX-10.1
from S-8 14 pages ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan
12/34/56
EX-10.1
from 8-K 13 pages Voting Agreement
12/34/56
EX-10.3
from 8-K 4 pages ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan Notice of Restricted Stock Grant
12/34/56
EX-10.2
from 8-K 4 pages ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan Notice of Restricted Stock Grant
12/34/56
EX-10.1
from 10-Q 27 pages [***] Certain Information Contained in This Document Has Been Omitted Based on a Court Order. Assignment and Technology Transfer Agreement Between Biosante Pharmaceuticals, Inc. and Cold Genesys, Inc. Dated as of November 15, 2010 Assignment and Technology Transfer Agreement
12/34/56
EX-10.34
from 10-K 9 pages Form of Indemnification Agreement
12/34/56